baber/WOPTO huggingface dataset:
Patent NZ-326927-A (NZ)
Title: Heat insulated case comprising a refrigerating unit with an ice bin
Inventor: LARSSON NILS
IPC: F25D3/06
Filed: 1997-01-21
Abstract: refrigerated freight container 1 comprises a heat insulated, substantially parallelepipedial case with a ceiling 2, two side walls and two end walls 5, 6, and a bottom 7.  A refrigerating unit with an ice bin 10 is positioned in the corner between one of the end walls 5 and the ceiling 2.  Around the ice bin 10 flow channels 12 for refrigerating air are disposed, whereby the flow of the refrigerating air is achieved by means of fans.  An inner ceiling 14 is disposed against the container ceiling 2 with a spacing therebetween and this spacing constitutes a flow path for the refrigerating air from the refrigerating unit.  The inner ceiling 14 ends at a distance from the inside of the side walls and that end wall 6 which is opposite to the one where the refrigerating unit is positioned.  A partition wall 15 extends between walls 3, 4 and from ceiling 2 to a position below the lower part of unit 10 and at a distance from unit 10.  Partition wall 15 in its upper part has openings (not shown) for letting refrigerating air through to the spacing above inner ceiling 14.  Partition wall 15 at its lower part has a sealing strip 19 directed towards the container room.
Patent NZ-335749-A (NZ)
Title: Formulation in the form of a patch for transcutaneous immunization comprising an antigen and an adjuvant
Inventor: GLENN GREGORY M
IPC: A61P37/04
Filed: 1997-11-14
Abstract: A formulation in the form of a dressing to form a patch for transcutaneous immunization comprises an antigen and an adjuvant for inducing an immune response when applied to intact skin. The adjuvant can be an ADP-ribosylating exotoxin.
Patent NZ-506792-A (NZ)
Title: Genetic constructs and genetically modified microbes for enhanced production of beta-glucosidase
Inventor: WHITE THERESA C
IPC: C12N1/21
Filed: 1999-03-09
Abstract: A genetic construct comprising a promoter in operative association with a xylanase secretion signal and a mature beta-glucosidase coding region of a beta-glucosidase gene.  The promoter is selected from the group consisting of Trichoderma cbh1, cbh2, eg1, eg2, eg3, eg5, xln1 and xln2 promoters.  The xylanase secretion signal is of a Family 11 xylanase gene and the beta-glucosidase gene is selected from the group consisting of Trichoderma, Aspergillus, Humicola and Fusarium beta-glucosidase gene.  The construct enhances beta-glucosidase production in a microbe.  The increased level of beta-glucosidase significantly increases the efficiency of hydrolysis of cellulose to glucose by cellulase enzymes, thereby enhancing the production of fuel ethanol from cellulose.
Patent NZ-510875-A (NZ)
Title: Fluorinated 3,4-dihydroquinoline derivatives used as NOS inhibitors in medicaments for treating neurodegenerative diseases
Inventor: BURTON GERARDINE ANNE
IPC: A61P29/00
Filed: 1999-11-10
Abstract: Described are compounds of formula (I), a method for producing them and to their use in medicaments as NOS inhibitors. In which R1 and R2 independently of one another, mean: a) hydrogen, b) C1-6 alkyl, c) OR8, d) NR8R9, e) CN, f) acyl, g) CO2R10, h) CONR8R9, i) CSNR8R9, R3 means: a saturated or unsaturated C1-5 alkene radical, which can be substituted in 1 to 4 places with OR8, NR1 R12 or C1-4 alkyl and in which 1 or 2 CH2 groups can be replaced by O, S(O)n, NR11, =N- or carbonyl, and which can be bridged with a methano, ethano or propano group, R4, R5, R6 and R7, independently of one another, mean a) hydrogen, b) halogen, c) S(O)nR8, d) OR8, e) COOR8, f) COR8, g) CONR8Rl3, h) CSNR8R13 i) C(NR8)NR9Rl3, j) NR14Rl5, k) C1 6 alkyl, which is optionally substituted with halogen, OR8, SR8,NR14R15, phenyl, 5- to 6- membered heteroaryl with 1 to 4 N, S or O atoms or C3-7 cycloalkyl, I) C3 7 cycloalkyl, m) C2-6 alkenyl, optionally substituted with phenyl or halogen, n) C2-6 alkinyl, optionally substituted with phenyl or halogen, o) C6 10 aryl, which is optionally substituted with halogen, CN, C1-4 alkyl, SR8 or OR8, p) 5 to 6 membered hetaryl with 1 to 4 N, O or S atoms, which contain a slightly condensed benzene ring and can be substituted with halogen, N02, cyano,-OR8, SR8, C1-4 alkyl, CF3 or NR8R13 q) CN, r) N02, s) CF3, t) OCF3, R4 and R5, R5 and R6 or R6 and R7 together with 2 adjacent carbon atoms form a 5- or 6-membered carbocycle, which can be substituted with NR14R15, R8, R9 and R10, independently of one another, mean: a) hydrogen, b) C1-6 alkyl, c) C6-10 aryl, which optionally is substituted with halogen or C1-4 alkyl. Such compounds are suitable for treating diseases of the cardiovascular system and for treating autoimmune and/or inflammatory diseases and they are well suited for inhibiting the neuronal NOS.
Patent NZ-517395-A (NZ)
Title: Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
Inventor: STEWART TIMOTHY A
IPC: C07K14/50
Filed: 2000-03-09
Abstract: FGF-19 (fibroblast growth factor-19) is used in the manufacture of a medicament for inducing leptin release from adipocyte cells, inducing a decrease in glucose uptake in adipocyte cells, for treating obesity, reducing total body mass, reducing the level of at least one of triglycerides and free fatty acids or in increasing the metabolic rate of an individual.
Patent NZ-521070-A (NZ)
Title: Mutated cyclin G1 protein
Inventor: GORDON ERLINDA MARIA
IPC: C12N5/09
Filed: 2001-03-01
Abstract: The application discusses the use of a mutated cyclin G1 protein. The said mutant protein may be utilized in the manufacture of a medicament for the treatment of a condition involving abnormal cellular proliferation in an animal. A method of preventing cell division is also discussed whereby the method comprises administering to a cell in vitro or ex vivo an effective amount of mutated cyclin G1.
Patent NZ-522431-A (NZ)
Title: High functional water containing titanium and method and apparatus for producing the same
Inventor: HIRATA YOSHIHIRO
IPC: A61K33/24
Filed: 2000-11-29
Abstract: A method and an apparatus for producing a water which contains fused titanium dissolved therein, characterized in that it comprises burning a mixed gas of oxygen and hydrogen in a high pressure water and fusing metallic titanium through the use of the resultant combustion gas; and an article for health, a medical article and a cosmetic which utilize biological activities of the resultant water containing fused titanium and high functional water.
Patent NZ-523994-A (NZ)
Title: Methods of preventing surgical adhesions
Inventor: BROWN COLIN
IPC: C08B30/18
Filed: 1999-05-13
Abstract: The application discloses the use of an aqueous formulation containing a polysaccharide dextrin in the manufacture of a medicament for preventing or reducing the incidence of adhesions in or associated with the body cavity. The dextrin contains more than 15% of polymers with a degree of polymerization greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity. This serves to separate tissues which otherwise may adhere to each other. (62) Divided out of 507832
Patent NZ-525129-A (NZ)
Title: An improved transformation method for creating pre-distorted images to event surfaces of televised events
Inventor: PARKER BRUCE PETER
IPC: G09F19/12
Filed: 2003-10-03
Abstract: A computer system for transforming an image into a pre-distorted image for application to an event surface such as a sports field, ice rink or advertising hoarding includes a processor arranged to transform the image. A plurality of fragments of the image are transformed as they would appear on a virtual spherical surface into transformed fragments of the image as they should appear on the event surface. This transformation is based on the geometric relationship between a camera, the virtual spherical surface and the event surface. The pre-distorted image is constructed from the transformed fragments and a representation of the re-distorted image is outputted.
Patent NZ-528298-A (NZ)
Title: Viral concentration process
Inventor: WOLF WILLIAM
IPC: C12Q1/70
Filed: 2003-09-18
Abstract: An apparatus for isolating a microorganism from a liquid, the apparatus comprising: a first endcap engageable with an inlet end of a hollow fibre filter, the first endcap including a first passage having an inlet egagable with a liquid input conduit; and an outlet into the filter; a second endcap engageable with an outlet end of the hollow fibre filter, the second endcap including a second passage having an outlet engagable with a liquid return conduit, and an inlet from the filter; and the first passage and the second passage being independently sized such that in conjunction with a flow restriction means which restricts a flow of the liquid through the second passage, a predetermined exit liquid flow rate in the range of from 0.25l/min to 3.0l/min from at least one permeate outlet of the filter is achieved; the microorganism is captured within the hollow fibre filter; and the maximum working pressure of the filter is not exceeded.
Patent NZ-529098-A (NZ)
Title: Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
Inventor: CORBETT THOMAS HUGHES
IPC: C07D249/08
Filed: 2002-05-24
Abstract: A compound of Formula I, wherein: X is O or NH ; R1 is hydrogen, halo, C1-C6 alkyl, C1-C4 alkoxy, C1-C4 alkylthio, CF3, OCF3, SCF3, (C1-C4 alkoxy) carbonyl, nitro, azido, O (SO2) CH3, N (CH3) 2, hydroxy, phenyl, substituted phenyl, pyridinyl, thienyl, furyl, quinolinyl, or triazolyl ; R2 is hydrogen, halo, cyano, CF3, C1-C6 alkyl, (C1-C4 alkoxy)carbonyl, C1-C4 alkoxy, phenyl, or quinolinyl ; R2a is hydrogen or C1-C4 alkoxy; R2b is hydrogen or C1-C6 alkyl provided that at least one of R2a and R2b is hydrogen; R3 is hydrogen, halo, C1-C6 alkyl, CF3, or nitro; R3a is hydrogen, halo, or C1-C6 alkyl, provided that when R3a is C1-C6 alkyl, R3 is hydrogen and R4 is halo; and R4 is halo, C1-C6 alkyl, or CF3 provided that only one of R3 and R4 may be C1-C6 alkyl and provided that when R4 is halo or C1-C6 alkyl only one of R3 and R3a is hydrogen; or a pharmaceutically acceptable base addition salt thereof, provided that: a) when R3 and R4 are both chloro and R2 is hydrogen, R1 is bromo, iodo, C1-C4 alkoxy, C1-C4 alkylthio, CF3, OCF3, nitro, azido, O (SO2) CH3, N (CH3) 2, hydroxy, phenyl, substituted phenyl, pyridinyl, thienyl, furyl, or triazolyl; b) when R3 and R4 are both chloro and R1 is hydrogen, R2 is bromo, fluoro, CF3, C1-C6 alkyl, C1-C4 alkoxy, phenyl, or quinolinyl. Such compounds are useful in pharmaceutical compositions for the treatment of neoplasms, such as a tumor of the colon or rectum.
Patent NZ-533829-A (NZ)
Title: A Ladder clamp
Inventor: JALAVA TUOMO UURAS
Filed: 2004-06-29
Abstract: A ladder clamp having a pair of handle members, a first jaw, and a second jaw, the handle members being moveable wherein such movement causes the jaws to move, the first jaw having a gutter contacting portion and the second jaw having a ladder contacting portion, the clamp being formed such that when it is in use a worker can manipulate the handles by hand and can align the first jaw with a portion of guttering and the second jaw with the ladder adjacent the guttering such that movement of handle members causes the jaws to sandwich and exert pressure against a part of the ladder wherein both jaws substantially contact the ladder to secure the ladder to the guttering.
Patent NZ-536084-A (NZ)
Title: Engine for converting thermal energy to stored energy
Inventor: LEWELLIN RICHARD L
IPC: F03G6/00
Filed: 2003-03-27
Abstract: An engine for converting thermal energy to stored fluid energy includes expansion cylinders (61a-f) with expansion chambers (62a-f) and flexible membranes (63a-f). Heating and cooling of working fluid inside the cylinders is carried out by fluid supply lines (73, 71) communicating with external heat resources and sinks. Pressure accumulator (66a) is adapted to store a pressurised fluid (64a-f), such as hydraulic oil, from the individual cylinders. In use, this pressurised fluid is delivered at an elevated and above a minimum threshold pressure level, irrespective of the irregularities of the movement of the expansion cylinders.
Patent NZ-538503-A (NZ)
Title: Seismic base isolation by electro-osmosis during an earthquake event
Inventor: HOCKING GRANT
IPC: E02D27/34
Filed: 2003-08-21
Abstract: A method and system of isolating a structure and soil mass from earthquake induced vibration by inducing soil liquefaction beneath a structure during an earthquake event, by monitoring local seismic precursor events, such as early arrival ground motion using an accelerometer, predicting the onset of a major earthquake tremor and energizing conductors in the ground by a dc power source for moving the ground water by electro-osmosis towards a suitable isolation layer, whereby raising the pore water pressure in the isolation layer and thus preferentially inducing localized soil liquefaction of the particular isolation layer during the earthquake event and thus isolating the structure and soil above the particular soil horizon from the upward propagating shear wave ground motions arising from the earthquake event.
Patent NZ-543263-A (NZ)
Title: 1,2,4-oxadiazole benzoic acid compounds
Inventor: KARP GARY MITCHELL
IPC: A61K31/4245
Filed: 2004-04-09
Abstract: Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification. The compounds are modulators of premature translation termination or nonsense-mediated mRNA decay and are useful in the treatment of genetic diseases such as autoimmune diseaases, blood diseases, collagen diseases, diabetes, inflammatory diseases and central nervous system diseases including arthritis, rheumatoid arthritis, graft versus host disease, multiple sclerosis, muscular dystrophy, late infantile neuronal ceroid lipofuscinosis, Duchenne muscular dystrophy, Alzheimer's disease, Tay Sachs disease, neurodegenerative diseases, Parkinson's disease, hemophilia, Von Willebrand disease, ataxia-telangiectasia, beta-thalassemia, kidney stones, osteogenesis imperfecta, cirrhosis, familial polycythemia, immunodeficiency, kidney disease, cystic fibrosis, familial hypercholesterolemia, retinitis pigmentosa, amyloidosis, atherosclerosis, giantism, dwarfism, hypothyroidism, hyperthyroidism, aging, obesity, Niemann Pick's disease, Marfan syndrome and cancer.
Patent NZ-545207-A (NZ)
Title: A method and apparatus for physiological testing and in particular for measuring the performance of human joints.
Inventor: CRESWICK RICHARD
IPC: A61B5/16
Filed: 2004-08-05
Abstract: A device and method to test the sincerity of physical effort of an individual. The device has a moveable member (20), a sensor (14) for measuring force applied to the shaft; and a resistance means (32) to vary the resistance to movement of the moveable member. The relationship between the varied resistive force applied to the moveable member and the measured force may be determined to establish the sincerity of effort of the user.
Patent NZ-552578-A (NZ)
Title: Substituted oxindol derivatives and medicaments containing the same
Inventor: LUBISCH WILFRIED
IPC: A61K31/454
Filed: 2005-07-13
Abstract: Disclosed is a compound of substituted oxindol derivatives of formula (1) their tautomeric, enantiomeric and/or diastereomeric forms as well as the physiologically compatible salts of the derivatives of formula (1), where in the substituents are as defined in the specification. Also disclosed is the method of producing a compound of formula (1) and the use of the compound of formula (1) wherein the medicament is useful for the treatment and/or prophylaxis of vasopressin-dependent or oxytocin-dependent diseases.
Patent NZ-553237-A (NZ)
Title: Peristaltic pump unit for medical infusion having a housing with removably mounted door
Inventor: HAYLOR NICHOLAS BRYANT
IPC: A47B91/04
Filed: 2005-07-13
Abstract: A peristaltic pump unit for medical infusion is disclosed. The pump unit comprises a peristaltic assembly (26) and a counter surface or anvil facing the peristaltic assembly (26). The anvil is provided by the inner surface of a door (30) that is pivotally mounted on a housing of the unit. The door (30) is non-destructively removable and replaceable. A flexible resilient tube (36) forming part of a medical fluid delivery line is extended between the peristaltic assembly (26) and the counter surface or anvil provided by the door (30). The medical fluid delivery line has first and second colour coded fittings (38, 40) spaced along upstream and downstream of the peristaltic assembly (26) for ease of correct orientation.
Patent NZ-555163-A (NZ)
Title: Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
Inventor: KANWAR JAGAT RAKESH
IPC: A23L1/00
Filed: 2007-05-14
Abstract: Disclosed is the use of milk fat or a milk fat analogue in the preparation of a medicament for administration to a subject at risk of developing, suffering from, or being treated for mucositis. Also disclosed is a composition comprising about 2 grams to about 210 grams of milk fat or a milk fat analogue and from about 0.7 grams to about 210 grams of one or more anti-tumour agents.
Patent NZ-556709-A (NZ)
Title: Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
Inventor: NEWMAN STEPHEN
IPC: C13K5/00
Filed: 2006-02-06
Abstract: Disclosed is a process for forming lactose suitable for use in a pharmaceutical formulation, comprising: providing a plurality of lactose particles containing no more than 10% w/w of particles with a volume average particle size of 70 microns or less; milling the particles to yield a plurality of milled lactose particles with an average particle size (D50) ranging from about 50 microns to about 100 microns; and classifying the particles into at least two fractions comprising a fine fraction and a coarse fraction, wherein the fine fraction has an average particle size (D50) ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size (D50) ranging from about 40 microns to about 250 microns.
Patent NZ-568364-A (NZ)
Title: One way valve for combustion tool fan motor for unidirectional air flow past motor
Inventor: MOELLER LARRY
IPC: B25C1/08
Filed: 2006-10-06
Abstract: A combustion nailer (10) having a combustion power source (14) defining a fan motor chamber (50) having at least one chamber wall (52, 54) and a motor shaft hole (56) . A fan motor (44) is disposed in the fan motor chamber (50) and has a motor shaft (42) projecting through the motor shaft hole (56). A one way valve (60) is associated with the chamber (18) and the motor and is configured for allowing unidirectional airflow through the hole (56) past the motor (44), and preventing airflow in the opposite direction.
Patent NZ-573477-A (NZ)
Title: Plant for the vaporization of LNG wherein part of the vaporised LNG are not sent to storage in the turbine
Inventor: CICCARELLI LIBERATO GIAMPAOLO
IPC: F17C9/04
Filed: 2007-06-05
Abstract: Disclosed is a plant for the vaporisation of liquefied natural gas or LNG (1). The plant comprises transformation means of an energy source for obtaining electric power during the vaporization operation by means of thermal exchange. The transformation means comprises at least a first turbine (T1) and a second turbine (T2). Vaporized part (5) of the LNG (1) that is not sent for storage in a reservoir (G) is burnt and expanded in the first turbine (T1). Heated compressed permanent gas is expanded in the second turbine (T2).
Patent NZ-575988-A (NZ)
Title: A fixing system for cladding
Inventor: CARBINES RICHARD JAMES
IPC: E04F13/00
Filed: 2006-09-05
Abstract: A fixing device (30) for securing cladding boards (28) to the framing (26) of a building in a partially overlapping relationship, each board having front and rear faces with a recess (42) being provided in and along the rear face. The fixing device is adapted to co-operate with a number of other fixing devices, the devices being supported by the framing and being spaced apart relative to one another and arranged in rows, each row of fixing devices being arranged to support a board or row of boards and each fixing device having an engagement portion (40) that is arranged to engage with a section of the recess of a board to, in co-operation with a number of other fixing devices of that row also engaging with a section of the recess, support the board in place on the framing. The fixing device is a wedge-shaped component. (62) Divided Out of 549708
Patent NZ-577042-A (NZ)
Title: Compounds for inhibiting mitotic progression
Inventor: CLAIBORNE CHRISTOPHER F
IPC: C07D487/04
Filed: 2007-11-14
Abstract: Disclosed are benzazepin-amino compounds represented by general formula (I), such as 4-{ [9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid. Also disclosed is the use of the compounds of formula (I) for treating Aurora kinase-mediated disorders such as cancer.
Patent NZ-581856-A (NZ)
Title: Amine salts of the CRTH2 antagonist {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid
Inventor: LY TAI WEI
IPC: A61K31/33
Filed: 2008-06-18
Abstract: Disclosed is a crystalline salt comprising a pharmaceutically acceptable amine and the compound {4,6-bis(dimethylamino)-2-(4-(4-(tritluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid (the compound of Formula (I), or a hydrate or solvate thereof. Also disclosed is the use of the salt to treat CRTH-2 mediated diseases.
Patent NZ-589469-A (NZ)
Title: Niacin and NSAID combination for reducing niacin-induced flushing
Inventor: WETTERAU JOHN R
IPC: A61P25/34
Filed: 2009-05-20
Abstract: The disclosure relates to a pharmaceutical composition suitable for preventing or reducing niacin-induced flushing, wherein the pharmaceutical composition comprises: niacin microparticles having a pH-dependent release profile, and aspirin microparticles having a pH-independent release profile, wherein the niacin microparticles have a reduced capacity to provoke a cutaneous flushing reaction in a subject; wherein the aspirin microparticles are present in an amount effective to reduce the cutaneous flushing caused by the niacin; wherein there is a lag time between release of aspirin and release of niacin following administration of the composition; and wherein the amount of aspirin in the composition is between 80 mg and 500 mg that is released based on an aspirin release profile, wherein about 70% to 90% of aspirin AUC is released over a period of time of 2 to 16 hours following administration of the composition, or wherein the aspirin concentration in plasma is greater than 5% of Cmax over a period of time of 2 to 16 hours following administration of the composition. These pharmaceutical compositions are suitable for preventing or reducing niacin-induced flushing.
Patent NZ-590588-A (NZ)
Title: Sorting animals after milking to enter grazed paddock based on nutritional needs and/or animal production capacity
Inventor: DE VILLIERS PIERRE
IPC: A01K1/00
Filed: 2009-07-29
Abstract: 590588 A method is provided for management of animals in an area (11) including a plurality of grazing paddocks (12a-f ), in which the animals graze, and a milking area (13), in which the animals are milked, wherein the milking area is accessible from each of the grazing paddocks and each of the grazing paddocks is accessible from the milking area via a sorting gate arrangement (17a, 17c). According to the method each of a plurality of animals which have grazed in the grazing paddocks is identified (21) and milked (22) in the milking area. A nutritional need and/or a milk production capacity of each of the animals which have been identified and milked is/are established (23). Finally, each of the animals is automatically guided (24) by means of the sorting gate arrangement, subsequent to the milking of the animal, to enter a selected one of the grazing paddocks depending on the nutritional need and/or the milk production capacity of the animal.